Clinical Trial Update: Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the efficacy and safety of ruxolitinib for hair regrowth in patients with Autoimmune Polyendocrinopathy Candidiasis Ectod…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alopecia Areata
• Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced), Alopecia Areata | Phase 2 | Status: RECRUITING